Comprehensive Pain Management: Documentation, Assessment, and Treatment Guidelines
Documentation Requirements
- A pain management clinic note must systematically record patient demographics, pain characteristics, treatment history, physical findings, and a detailed management plan that includes pharmacologic, non‑pharmacologic, and interventional strategies, as well as mandatory patient education and safety‑monitoring protocols. 1
- The referring provider’s contact information should be documented to facilitate care coordination. 4
- All comorbid conditions that may affect analgesic choices—such as cardiovascular disease, renal impairment, hepatic dysfunction, peptic‑ulcer disease, bleeding disorders, thrombocytopenia, and substance‑use history—must be recorded. 1
- Psychiatric history (depression, anxiety, substance‑abuse) is essential for opioid prescribing decisions. 3
- For each opioid prescribed, record the specific agent, dose, frequency, and total daily morphine‑milligram equivalents (MME). 2
- NSAID or COX‑2 inhibitor prescriptions must include the exact drug and dose. 1
- Acetaminophen dosing should be documented as total daily amount. 1
- Concomitant medications that influence NSAID safety (anticoagulants, corticosteroids, nephrotoxic agents, chemotherapy) must be listed. 1
- Allergic reactions should be described precisely, distinguishing true IgE‑mediated allergies from side‑effects or intolerances. 2
Pain Assessment
- Record numerical pain intensity on a 0‑10 scale (current, average, worst, and least pain over the past 24 h). 5
- Classify the primary pain diagnosis as neuropathic, nociceptive, centrally mediated, or mixed. 7
- Identify contributing factors such as psychological distress, sleep disturbance, and functional limitations. 7
- Document medication‑related problems, including side‑effects, inadequate analgesia, and toxicity risk factors. 1
- Recognize high‑risk features for NSAID complications: age ≥ 60 y, history of peptic ulcer, alcohol ≥ 2 drinks/day, anticoagulant use, or organ dysfunction. 1
- Conduct opioid‑risk assessment focusing on substance‑abuse history and psychiatric comorbidities. 3
Pharmacologic Management
- Opioid‑tolerant patients: For breakthrough dosing, calculate 10‑20 % of the 24‑hour opioid requirement; reassess after 60 min and increase breakthrough dose by 50‑100 % if pain persists. 5
- NSAID therapy: Use the previously effective agent; limit ibuprofen to a maximum of 3 200 mg per day in divided doses. 1
- NSAID safety: Never combine two NSAIDs (e.g., add a second NSAID to celecoxib) because of additive gastrointestinal, renal, and cardiovascular toxicity. 5
- COX‑2 inhibitors: Preferred for patients at high gastrointestinal risk due to lower GI side‑effects and lack of platelet inhibition. 1
- Non‑acetylated salicylates: Offer choline‑magnesium salicylate 4.5‑5 g/day or salsalate 2‑3 g/day as alternatives for patients with bleeding risk. 1
- Adjuvant analgesics:
- First‑line for centrally mediated/functional pain: low‑dose tricyclic antidepressant (amitriptyline or nortriptyline 10‑25 mg at bedtime). 7
- If tricyclics are not tolerated: duloxetine 30‑60 mg daily (SNRI). 7
- For spasmodic pain: anticholinergic antispasmodic (dicyclomine) is more effective than direct smooth‑muscle relaxants. 7
- Bowel regimen: Implement mandatory prophylaxis for opioid‑induced constipation. 2
Monitoring & Safety
- Laboratory monitoring for NSAIDs:
- Vital signs: Monitor blood pressure for NSAID‑induced hypertension. 6
- Mental status: Assess for sedation, confusion, or altered cognition at each visit. 2
- Pain reassessment: Use the numerical rating scale at every patient contact. 5
- Adverse‑effect surveillance: Track nausea, dizziness, drowsiness, constipation, and sedation. 5
- Safety warnings: Patients must be advised not to operate machinery or drive while taking sedating medications. 2
- Tramadol contraindications: Avoid in patients with seizure history, respiratory compromise, or significant liver/renal impairment. 5
Patient Education (Mandatory Written Documentation)
- Provide a written medication list with purpose and dosing instructions. 2
- Explain expected side‑effects and management strategies. 2
- List medications that should be discontinued. 2
- Key messages to convey:
- Effective pain relief is medically important; unnecessary suffering offers no benefit. 3
- Regular scheduled dosing improves control of persistent pain. 1
- Multiple treatment options exist if the current regimen is ineffective. 1
- Potent analgesics must be taken exactly as prescribed; patients should not adjust doses without provider input. 1, 8
- Controlled substances must be stored securely at home. 2
- Alcohol and illicit substances must not be mixed with prescribed analgesics. 2
- When used appropriately for pain, the risk of addiction is low. 2
- Medications remain effective if needed later, addressing tolerance concerns. 2
When to Contact Provider
- Issues obtaining or taking medications. 2
- New, changed, or uncontrolled pain. 2
- Persistent nausea/vomiting preventing oral intake for > 1 day. 2
- No bowel movement for ≥ 3 days. 2
- Difficulty arousing the patient from sleep during daytime. 2
- New confusion or altered mental status. 2
- Recurrence of original symptoms after medication discontinuation. 8
- Signs of gastrointestinal bleeding. 8
Follow‑Up Plan
- Schedule a telephone call or clinic visit within 1–2 weeks to evaluate symptom response and medication tolerance. 8
Critical Pitfalls to Avoid
- Do not prescribe opioids for chronic gastrointestinal pain, as this can cause narcotic bowel syndrome and worsen outcomes. 7
- Never combine multiple NSAIDs; doing so markedly raises serious adverse events without added analgesic benefit. 5
- Pain assessment must always include the patient’s self‑report; clinicians cannot infer severity without it. 2
- Written discharge instructions are mandatory; verbal education alone is insufficient for safe pain management. 2